Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Aflubin** is a complex homeopathic preparation used primarily for the prevention and treatment of influenza, common colds (ARVI), and as adjunctive therapy for inflammatory and rheumatic diseases with joint pain. It contains highly diluted active ingredients including Aconitum napellus D6, Bryonia cretica D6, Eupatorium perfoliatum D2 (or similar), Ferrum phosphoricum D12, Gentiana lutea D1, and Acidum lacticum D12, formulated in drops or sublingual tablets. The preparation exhibits anti-inflammatory, immunomodulatory, antipyretic, detoxifying, and claimed antiviral effects by stimulating interferon synthesis, enhancing cellular and local immunity, reducing fever, chills, runny nose, cough, headache, muscle/joint pain, and supporting recovery while preventing complications. Available in oral drops (e.g., 20ml, 50ml containing ~43% ethanol) and tablets, it is produced in Ukraine and marketed in Europe for symptomatic relief of flu-like symptoms.[1][2][5][8]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aflubin.